This is the authors' abstract. We don't add key points for this paper.
Background: Spinal muscular atrophy (SMA) is a rare genetic neuromuscular disease.Objective: Characterize direct costs associated with SMA management.Data source: Truven Health Analytics MarketScan claims data (2012–2016).Patients: Eligible patients had ≥2 SMA-related medical claims ≥30 days apart. Patients were matched (1:1) to controls by birth year, gender, and geographic region. Patients were categorized as having infantile, child, or juvenile SMA based on diagnosis at age <1, 1–3, or 3–18 years, respectively.Main outcome measures: Annual inpatient and outpatient insurance claims and costs (2019 USD) for cases versus controls.Results: Fifty-eight, 56, and 279 cases and controls comprised the infantile, child, and juvenile cohorts, respectively. Cases had more inpatient claims than controls (infantile: 60.3% vs 1.7%; child: 35.7% vs 3.6%; juvenile: 47.0% vs 4.3%; all P ≤ 0.002). Mean net payments for inpatient admissions were higher for cases versus controls (infantile: $118,609.00 vs $58.79; child: $26,940.01 vs $143.56; juvenile: $39,389.91 vs $701.21; all P ≤ 0.01), as were mean net payments for outpatient services (infantile: $55,537.83 vs $2,047.20; child: $73,093.66 vs $1,307.56; juvenile: $49,067.83 vs $1,134.69; all P ≤ 0.0002).Conclusions: Direct costs of SMA are tremendous, often >50-fold higher compared with matched controls. Efforts are needed to reduce costs through improved standards of care.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Belter et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: